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Background: Oncogenic mutations are common in thyroid cancers. While the frequently detected RAS-oncogene
mutations have been studied for diagnostic use in cytologically indeterminate thyroid nodules, no investigation has
studied such mutations in an unselected population of thyroid nodules. No long-term study of RAS-positive thyroid
nodules has been performed.
Methods: We performed a prospective, blinded cohort study in 362 consecutive patients presenting with clinically
relevant (>1 cm) thyroid nodules. Fine needle aspiration cytology and mutational testing were obtained for all
nodules. Post-operative histopathology was obtained for malignant or indeterminate nodules, and benign nodules
were sonographically followed. Histopathological features were compared between RAS- and BRAF-positive
malignancies. RAS-positive benign nodules were analyzed for growth or cellular change from prior aspirations.
Results: Overall, 17 of 362 nodules were RAS-positive. Nine separate nodules were BRAF-positive, of which eight
underwent surgery and all proved malignant (100 %). Out of the 17 RAS-positive nodules, ten underwent surgery, of
which eight proved malignant (47 %). All RAS-positive malignancies were low risk – all follicular variants of papillary
carcinoma, without extrathyroidal extension, metastases, or lymphovascular invasion. RAS-positivity was associated
with malignancy in younger patients (P = 0.028). Of the nine RAS-positive benign nodules, five had long-term
prospective sonographic follow-up (mean 8.3 years) showing no growth or signs of malignancy. Four of these
nodules also had previous aspirations (mean 5.8 years prior), all with similar benign results.
Conclusions: While RAS-oncogene mutations increase malignancy risk, these data demonstrate a low-risk
phenotype for most RAS-positive cancers. Furthermore, cytologically benign, yet RAS-positive nodules behave
in an indolent fashion over years. RAS-positivity alone should therefore not dictate clinical decisions.Background
Over the last two decades, the discovery of molecular
pathways critical to oncogenic transformation has dra-
matically altered our understanding of thyroid malig-
nancy. Reports initially suggested that nearly 70 % of
thyroid cancers harbor single gene mutations in the
BRAF or RAS pathways, or balanced translocations of
RET/PTC, or PAX8/PPARγ [1, 2]. More recently, reports
confirm an oncogenic mutation in 97 % of well-
differentiated papillary carcinomas [3]. Such mutations* Correspondence: ekalexander@partners.org
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needle aspiration (FNA) cytology specimens and on
post-operative histopathology. Many believe that the
synergistic use of microscopic and molecular analysis is
destined to improve the clinical management of this
illness [4].
Mutations or translocations identified in most thyroid
carcinomas are known to activate pathways regulating
cellular growth, development, and/or malignant trans-
formation, which has led to the assumption that thyroid
nodules harboring such mutations are either cancerous,
or at high risk for eventual malignant transformation
[5–7]. However, observational data question this as-
sumption as absolute and suggest that all such pathways
or activating mutations may not prove equally oncogenicis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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ing in a malignant fashion. In particular, clinical out-
comes of patients with mutations in the N-, K-, or H-
isoforms of the RAS gene are highly variable [7]. In con-
trast to homogeneous BRAF V600E mutations which
strongly associate with higher-risk papillary carcinoma,
initial observations suggest RAS mutations associate
with variable histology, ranging from benign disease, to
low-risk malignancy, to anaplastic carcinoma [7–10].
However, few prospective blinded assessments of RAS-
positive thyroid nodules (treated or untreated) have been
performed. Such an assessment is critically important, as
diagnostic testing for these mutations is now widely
available. To many clinicians, identification of an activat-
ing RAS mutation may prompt a belief that malignancy
has been identified [7]. This leads to downstream clinical
recommendations usually favoring surgical resection.
Such treatment is highly beneficial in many scenarios,
but for those with benign disease, has subjected the pa-
tient to unnecessary cost, operative morbidity, and sig-
nificant risk [11, 12]. Past experience involving papillary
microcarcinoma provides a cautionary parallel support-
ing the importance of further study of RAS-positive thy-
roid nodules. For decades, widespread belief that all
papillary carcinoma posed danger prompted recommen-
dations for active removal of such thyroid nodules [13, 14].
This was true even when nodules were smaller than 1 cm
and ultrasound confirmed the absence of abnormal adeno-
pathy. Prospective data debunked this belief, confirming
the indolent nature of these papillary microcarcinomas
[15]. Expert guidelines now recommend against evaluation
of most nodules <1 cm, and/or surgical treatment of sub-
centimeter papillary carcinomas [16, 17].
We performed a prospective study of clinically rele-
vant thyroid nodules, including ultrasound-guided FNA
and gene mutation analysis. Blinded mutational analysis
and histopathologic interpretation was performed. Our
goal was not to validate the performance of a molecular
diagnostic test on cytologically indeterminate nodules,
as such investigations have previously been per-
formed. Rather, we uniquely sought to evaluate the
molecular profiles of a large consecutive cohort of
thyroid nodules >1 cm presenting for FNA. By doing so,
we sought to understand the molecular profiles detected
in an unselected nodule population whether cytologically
benign, indeterminate, or malignant. Furthermore, as a
large proportion of our patients also participate in an on-
going prospective, long-term cohort study assessing the
natural history of thyroid nodules, we hypothesized that
several mutation-positive nodules would also have long-
term sonographic follow-up for analysis. If so, assessment
for potential malignant transformation – in particular
when observing the natural history of RAS-positive thy-
roid nodules – would be for the first time possible.Methods
We performed a prospective, blinded study of euthyroid
patients seeking care of thyroid nodules >1 cm in diam-
eter. Patients were referred to the thyroid biopsy clinic
at the Brigham and Women’s Hospital (Boston, MA,
USA) between July 2010 and October 2012, and evalu-
ated according to current clinical practice guidelines
[16]. Ultrasound evaluation was performed by one of
four radiologists with expertise in thyroid evaluation,
using a 6–15 mHz transducer. Following informed con-
sent, ultrasound-guided FNA was performed by one of
three thyroidologists. Three needle passes from the same
nodule using 25 g needles were rinsed into a liquid-
based solution (CytoLyt®; Cytyc Corp., Marlborough,
MA, USA), constituting a single aspiration. An add-
itional sample was then obtained and shipped to a
centralized CLIA-certified laboratory at Asuragen, Inc.
(Austin, TX, USA) where mutational analysis was per-
formed as part of the miRInform Thyroid® diagnostic test
[18]. As previously described, this test evaluates 17 dis-
tinct genetic alterations, including 14 BRAF, K-, N-, or
H-RAS mutations, and three PAX8-PPARγ and RET-PTC
rearrangements [18]. Of 391 nodules enrolled for initial
evaluation, 11 yielded insufficient nucleic acid for muta-
tional testing. A separate consecutive group of 15 separ-
ate nodules all showed an uncharacteristic molecular
result (double positive for PAX8-PPARG and RAS) sug-
gesting external cross-contamination during processing
of this series, and were therefore excluded. Three nod-
ules were excluded as a result of a protocol deviation
(one delayed shipping) or study dropout (n = 2). This
resulted in a final population of 362 nodules from 318
patients.
FNA cytology was classified according to the Bethesda
system for reporting thyroid cytopathology [19]. Benign
cytologic results most often prompted a conservative,
non-operative recommendation. Cytologically indeter-
minate and malignant nodules most often prompted a
recommendation for surgical resection. Midway through
this study, Afirma gene expression classifier (GEC) test-
ing became available, and was applied to a minority of
low-risk patients with initial atypia of undetermined sig-
nificance (AUS) cytology. If Afirma testing was benign,
nodules were treated similarly to those with benign
cytology [20]. Following thyroidectomy, histopathology
interpretation was performed, which frequently involved
multi-expert review and consensus. All histopathologic
interpretations were blinded to molecular results. Simi-
larly, molecular interpretation was performed without
knowledge of any clinical or pathologic findings. At study
completion, results were combined and interpreted.
The Brigham and Women’s Hospital thyroid nodule
clinic has prospectively enrolled all patients evaluated
between 1995–present in an ongoing clinical trial assessing
Medici et al. BMC Medicine  (2015) 13:184 Page 3 of 9the natural history of thyroid nodules [21]. We analyzed all
past and present thyroid sonographic imaging in patients
with RAS-positive, cytologically benign thyroid nodules.
For some of the patients, a separate ultrasound-guided
FNA of the target nodule had also been performed at an
earlier time point before enrollment in the current study.
This was usually at a separate facility or by a separate
provider.
For the purposes of this study, we sought to specific-
ally describe the histologic outcome of all thyroid nod-
ules positive for N-, H-, and K-RAS mutations, as these
mutations are common yet observations suggest a vari-
able phenotype. For RAS-positive nodules confirmed
malignant by histopathology, we documented the cancer
type and specific papillary thyroid carcinoma (PTC)
variant. Nodule size, as well as multifocality, lymphovas-
cular invasion, extrathyroidal extension, and local meta-
static adenopathy were similarly documented. For
RAS-positive nodules with benign cytology, we reviewed
all available sonographic and cytologic reports docu-
menting thyroid nodule size, abnormal adenopathy, or
other signs of malignant behavior, with a follow-up time
of at least 6 months. Growth was defined as a >20 %
change in the largest two nodule dimensions.
This protocol was approved by the Investigational
Review Board of the Brigham and Women’s Hospital,
and all patients provided written informed consent for
participation and publication of individual patient data,
including the data described in Tables 2 and 4. No pa-
tients received a stipend for participating in this study.
ANOVA was used to compare the mean age between pa-
tients with RAS-positive benign and malignant nodules.
Statistical analysis was performed using SPSS version 22
(SPSS IBM, Armonk, NY, USA), and a P value <0.05 was
considered significant.
Results
We prospectively enrolled 318 patients with 362 clinic-
ally relevant thyroid nodules (>1 cm), whose baseline
characteristics are shown in Table 1. Following blinded
molecular analysis, 17 nodules were positive for mutations
in the K-, N-, or H- RAS genes, while nine separate nod-
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aHistologically proven; bof the 362 nodules, 63 were referred to surgery because of non-
nodules, two underwent surgery and were proven benign. The third nodule underwent
were referred to surgery because of indeterminate or malignant cytology, of which eighnodules were positive for translocations involving the
PAX8-PPARγ genes, while no RET-PTC translocations
were found. Ultimately, 33 of 362 (9.1 %) nodules proved
malignant following surgical resection and blinded histo-
pathologic assessment, including eight BRAF-positive and
eight RAS-positive nodules. Of the 17 RAS-positive nod-
ules, ten were referred to surgery because of abnormal or
malignant cytology, while seven did not have surgery as
their biopsy was benign (six cytologically ‘benign’; one
nodule cytologically AUS but subsequent ‘benign’ GEC).
Of the ten RAS-positive nodules referred to surgery, eight
proved histologically malignant, while two were histologi-
cally benign. In summary, 8 of 17 RAS mutation-positive
nodules (47 %) were malignant by microscopic analysis,
while the remainder were benign.
RAS-positive thyroid malignancies
Table 2 shows the characteristics of the RAS-positive
thyroid malignancies. All (n = 8) were follicular variants
of PTC (fvPTC), and all demonstrated very low-risk
characteristics. Specifically, there was no evidence of
lymphovascular invasion, extrathyroidal extension, local
lymph node metastases, or distant metastases in any
RAS-positive thyroid cancers. Furthermore, all were en-
capsulated, or partially encapsulated/well-circumscribed
malignancies, and there were no disease-specific deaths.
For comparison, we evaluated the histologic characteristics
of the BRAF-positive thyroid malignancies. Compared to
the RAS-positive malignancies, the BRAF-positive malig-
nancies were equal in size (2.1 cm). However, they had less
favorable histological characteristics as shown in Table 3.
These data suggest a more indolent phenotype among
many RAS-positive thyroid cancers.
RAS-positive benign thyroid nodules
Nine RAS-positive thyroid nodules proved benign (two
histologically benign; six cytologically benign; one benign
GEC). Characteristics of the RAS-positive benign nod-
ules are shown in Table 4. These nodules averaged
2.1 cm in largest dimension at study entry. While four
nodules had not been previously evaluated in our thy-
roid nodule clinic, five nodules had undergone previous
sonographic imaging and evaluation, including four with-positive subgroup












8 HRAS+ (3 G12V, 2 Q61K, 2 Q61R, 1 G13R)
7 NRAS+ (6 Q61R, 1 Q61K)
2 KRAS+ (1 G12V)
benign cytology, of which 33 proved malignant; cof the three PAX8-PPARγ-positive
Afirma GEC testing, which was also benign; dof the 17 RAS-positive nodules, ten
t proved malignant. GEC, gene expression classifier
Table 2 Characteristics of RAS-positive thyroid malignancies
Subject
number
Sex Age (years) RAS mutation Nodule size (mm) and
parenchyma






1 Female 27 HRAS G12V 10 × 7 × 4 Solid No
calcifications
Follicular neoplasm PTC multifocal, 1.2 cm Partially-encapsulated/
well-circumscribed
No No No




PTC follicular variant, 1.1 cm Partially-encapsulated/
well-circumscribed
No No No




PTC follicular variant, 2.6 cm Partially-encapsulated/
well-circumscribed
No No No




PTC follicular variant, 1.8 cm Encapsulated No No No




PTC follicular variant, 1.1 cm Partially-encapsulated/
well-circumscribed
No No No




PTC follicular variant, 1.0 cm Encapsulated No No No
7 Female 44 NRAS Q61R 18 × 14 × 12 Solid No
calcifications
Follicular neoplasm PTC follicular variant, 1.6 cm Encapsulated No No No




PTC follicular variant, 3.1 cm Encapsulateda No No No












Table 3 Comparison of RAS-positive and BRAF-positive papillary thyroid cancers
Mutation Positive predictive value
(test specificity)






RAS-positive cancers (n = 8) 47 % (97.3 %) Range: 1.0–3.6
Median: 1.9
8 – follicular variant PTC 0/8 (0 %) 0/8 (0 %) 0/8 (0 %)
BRAF-positive cancers (n = 8a) 100 % (100 %) Range: 1.0–4.8
Median: 1.4
6 – classical variant PTCb
1 – tall cell variant PTC
1 – follicular variant PTC
5/8 (62.5 %) 1/8 (12.5 %) 1/8 (12.5 %)
aNine BRAF mutations were detected in the cohort. However, one patient did not pursue surgery because of other medical conditions. Therefore eight BRAF-positive cases
are shown; bincluding two classical variant PTCs with tall cell features. PTC, papillary thyroid carcinoma
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repeated sonographic assessment of five RAS-positive
cytologically benign nodules over time. No significant
nodule growth was confirmed in all five (100 %) cases over
a mean duration of 8.3 years (range: 3.1–24.0 years). Fur-
thermore, no abnormal adenopathy or other sonographi-
cally worrisome features were identified throughout
follow-up in all patients. For comparison, we randomly se-
lected age and sex matched mutation-negative controls at
a 3:1 ratio (i.e., 15 controls) and analyzed the same param-
eters. Over a comparable mean follow-up time of 7.5 years
(range: 2.8–24.0 years), an average 4.6 mm increase in
largest dimension was observed from these cytologically
benign, mutation-null nodules.
Four of six RAS-positive, cytologically benign nodules
had undergone a separate secondary biopsy at a time
point preceding entry into this current study. All four
previous aspirates (100 %) were cytologically benign
when performed at mean 5.8 years prior to study entry,
confirming no change in cellular morphology to the
present. One other nodule demonstrated AUS at cy-
tology on study entry, but was benign on subsequent
GEC testing. This nodule was therefore considered be-
nign. Finally, we compared the age of patients with RAS-
positive thyroid nodules which proved malignant to
those which proved benign. Patients with RAS-positive
benign nodules were on average 13 years older (55.1 (3.7)
(mean (SD)) versus 41.9 (4.0) years; P = 0.028) than pa-
tients with RAS-positive malignant nodules.
Discussion
Over the last decade, our understanding of the molecular
pathways underpinning thyroid cancer has dramatically
increased. This has improved care, though simultaneously
fostering many clinical assumptions influenced by the
population being studied. Nearly all investigations of mo-
lecular mutations have been performed on cancerous or
cytologically indeterminate thyroid nodules. Importantly,
this was not the goal of our study. We sought to present
the first blinded, prospective analysis of RAS mutations in
a general cohort of patients presenting with nodular dis-
ease, to better understand the meaning of such mutations
and the natural history of RAS-positive nodules. Our datademonstrate a variable and generally low-risk phenotype
among most RAS-positive nodules. RAS-positive status
predicts thyroid cancer in 47 % of cases, though is also as-
sociated with a large proportion of thyroid nodules with
benign histology, benign cytology, and indolent clinical
characteristics during long-term conservative follow-up.
In our population, RAS-positive thyroid cancers were
uniformly low risk – all histologically confirmed to be
fvPTC and encapsulated, and all without lymphovascular
invasion, extrathyroidal extension, or local lymph node
metastases. While many have argued that RAS-positive
nodules are destined to behave in a malignant fashion,
our data suggest this assumption should be viewed with
caution. Several of the RAS-positive, cytologically benign
thyroid nodules in our study cohort had previously been
aspirated at an average of 5.8 years prior. This confirms
the lack of meaningful cellular transformation over time.
Furthermore, highly accurate sonographic assessment of
these nodules during a mean 8-year follow-up (and up
to 24 years in one patient) confirmed no growth con-
cerning for malignant transformation. Together, these
data suggest a far more indolent phenotype inherent to
many RAS-positive thyroid nodules than previously
described.
In the current study, all RAS-positive malignancies
were fvPTCs (Table 3), while there were no RAS muta-
tions detected in classical variant PTCs. This is interest-
ing in the light of the results of the study of Castro
et al., who showed that fvPTCs are molecularly more
similar to follicular carcinoma than to classical variant
PTCs [22]. This included a higher percentage of RAS
mutations in fvPTCs than generally reported in classical
variant PTCs.
The ability of activated mutant RAS to induce thyroid
neoplasia in vitro has been well established [23–25]. Fur-
thermore, the cellular pathways stimulated by mutated
RAS, including the MAPK and PI3/AKT signaling path-
ways, have been linked to thyroid tumorigenesis [23, 26].
However, the RAS gene encodes a family of three
isoforms, NRAS, HRAS, and KRAS, with numerous dif-
ferent mutations described. Some studies have demon-
strated a tight association between mutated RAS and
follicular thyroid carcinoma, while others confirm a high
Table 4 Characteristics and sonographic follow-up of RAS-positive benign nodules
Subject
number




Nodule size (mm) and
parenchyma at study entry
FNA cytology at
study entry
Previous or subsequent ultrasound Duration of sonographic
follow-up
Previous FNA cytology
(date, size (mm), parenchyma) (date, result)
9 Female 52 HRAS G12V 11/2010, 18 × 5 × 11, <25 % Cystic Benign 02/2013, 16 × 11 × 9, Cystic (<25 %) 3.9 years (no growth) Not performed
10/2014, 17 × 10 × 8, N/A
10 Female 52 HRAS Q61K 03/2012, 16 × 14 × 9, Solid Benign 09/2008, 17 × 12 × 11, Solid 3.4 years (no growth) 11/2008, Benign cytology
11/2008, 17 × 10 × 10, N/A
01/2012, 16 × 15 × 9, Solid
11 Female 37 KRAS G12V 09/2011, 15 × 11 × 9, <25 % Cystic Benign - N/A Not performed
12 Female 54 KRAS G12V 10/2010, 14 × 14 × 8, Solid Benign 07/1990, 13 × 12 × 7, N/A
10/1993, 14 × 12 × 8, N/A
05/1998, 15 × 13 × 8, Solid
06/1998, 15 × 13 × 8, Solid
10/1999, 15 × 13 × 7, Solid
07/2003, 15 × 14 × 7, Solid
07/2005, 14 × 14 × 8, Solid
10/2007, 15 × 14 × 7, Solid
01/2008, 13 × 12 × 7, Solid
08/2009, 14 × 13 × 8, Solid
09/2010, 16 × 15 × 9, Solid
07/2011, 16 × 13 × 7, Solid
01/2012, 15 × 15 × 7, Solid
01/2013, 16 × 15 × 8, Solid
07/2014, 15 × 14 × 9, Solid
24.0 years (no growth) 06/1998, Benign cytology
13 Female 54 NRAS Q61K 04/2011, 15 × 12 × 11, <25 % Cystic Benign 05/2006, 15 × 9 × 9, Cystic (<25 %)
09/2006, 14 × 10 × 9, Cystic (<25 %)
06/2009, 12 × 11 × 11, Cystic (<25 %)
04/2011, 16 × 13 × 10, N/A
04/2012, 17 × 12 × 12, Cystic (<25 %)
06/2013, 15 × 12 × 10, Cystic (<25 %)
7.0 years (no growth) 09/2006, Benign cytology
14 Female 30 NRAS Q61R 09/2011, 16 × 14 × 9, Solid Benign 08/2008, 13 × 13 × 8, Solid
12/2008, 13 × 13 × 9, Solid
07/2011, 15 × 14 × 8, N/A
3.1 years (no growth) 12/2008, Benign cytology
15 Female 62 NRAS Q61R 01/2012, 17 × 14 × 12, Solid AUS + Afirma GEC
‘Benign’
N/A N/A 04/2012, AUS
05/2012, Afirma GEC: ‘benign’
16 Female 64 HRAS G12V 11/2010, 23 × 19 × 15, <25 % Cystic AUS N/A N/A 01/2011, Surgerya: benign
histology
17 Male 46 HRAS Q61K 03/2012, 56 × 45 × 33, Solid Follicular neoplasm N/A N/A 05/2012, Surgerya: benign
histology
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fvPTC [7]. These findings confirm that the MAPK and
PI3/AKT cellular pathways are intimately involved in
cellular growth and differentiation, but also demonstrate
that numerous genetic and epigenetic factors likely con-
tribute to the clinical phenotype. This is exemplified by
recent analysis of the thyroid cancer genome atlas [3].
Our data support such findings, while broadening our
understanding specific to RAS-positivity in a large popu-
lation, inclusive of mostly benign nodules.
Other published data support our findings. It is again
important to note that most investigations have studied
RAS mutations only in populations with malignant or in-
determinate cytology [2, 27–29]. Similar to us, however,
Moses and colleagues performed a blinded and prospect-
ive mutational analysis of 417 patients presenting with
nodular disease [9]. In this cohort, 21 RAS-positive nod-
ules were identified (4.6 % prevalence), very similar to
the 4.7 % detected in our population. While 12 RAS mu-
tations were identified among their 194 patients with ab-
normal cytology, nine additional RAS mutations were
identified in the remaining 257 benign nodules. In total,
6 of 21 (29 %) RAS-positive nodules proved histologi-
cally malignant. This rate is comparable to our finding
of 47 %. Unlike our investigation, however, no previous
sonographic analysis or FNA were performed. Nonethe-
less, these data independently support our conclusion
that RAS mutations are commonly detected in benign
nodules.
While the number of samples in the current study is
too limited from which to draw firm conclusions regard-
ing the distribution of RAS mutation subtypes in benign
or malignant nodules, it is noteworthy that two KRAS
mutations were detected in benign nodules, while none
were detected in malignant nodules. Interestingly, Rad-
kay and colleagues have also studied 204 FNA cases with
RAS mutations (mostly indeterminate cytology) with
corresponding surgical resection pathological specimens,
similarly demonstrating that mutations in KRAS were
associated with a significantly lower risk of carcinoma
(41.7 %) compared to nodules with HRAS (95.5 %) and
NRAS (86.8 %) mutations [29].
It is unclear why RAS-positive thyroid nodules behave
in a less virulent manner, though several hypotheses can
be considered. One possibility is that the different RAS
mutations affect downstream protein function to vari-
able degrees. This hypothesis is supported by parallel
evidence observed in medullary thyroid carcinoma pa-
tients with activating RET mutations, in which over 50
unique mutations are described [30]. These data confirm
that different genetic mutations in the same oncogene
lead to variable malignant risk. Separately, it is increas-
ingly likely that a two-hit hypothesis is necessary for ma-
lignant transformation in many RAS-positive nodules,especially those associated with aggressive disease [31].
Further investigation is required to better address these
hypotheses.
Importantly, we do not advocate performing RAS-
mutational testing on all thyroid nodules at time of
presentation for several reasons. First, FNA cytology
proved more accurate than RAS-analysis, as all thyroid
malignancies were identified in nodules with indetermin-
ate or malignant cytology. Second, such an approach has
not been shown to be cost-effective nor to produce an im-
proved health outcome. We realize, however, that some
may nonetheless argue that detection of RAS-mutational
status is important beyond simply its use in cytologically
indeterminate FNAs. RAS-positive nodules indeed carry a
higher risk for malignancy compared to RAS-negative
nodules, and RAS-positive status may also affect prognos-
tic and therapeutic decisions once malignant [8].
Our data do lend preliminary support for surgical re-
moval of RAS-positive nodules in younger individuals
with non-benign cytology, but question this approach in
RAS-positive benign nodules. The majority of our study
cohort with cytologically benign, yet RAS-positive nod-
ules have been closely followed by clinical and sono-
graphic assessment. During a follow-up that ranged
from 3–24 years, no significant growth or malignant
transformation was documented. Furthermore, repeat
aspiration confirmed the presence of consistently benign
cytology. Thus, any recommendation for thyroidectomy
must balance the presumed benefits of such a procedure
against its known risks [11, 12].
We acknowledge limitations to our study. Notably, we
recruited patients from a single institution. However, the
fact that our clinic evaluates >95 % of all patients seek-
ing thyroid nodule care in our healthcare system im-
proves generalizability of these results and limits
selection bias. We similarly acknowledge the lack of uni-
versal long-term follow up of all RAS-positive nodules.
Though our data depict no growth via highly accurate
sonographic follow-up of five such patients, it is possible
such benign nodules would indeed transform into malig-
nant processes over enough time. Importantly, however,
our study also confirmed an impressive low-risk histo-
logic profile to most RAS-positive malignancies. Thus, if
an observational strategy was followed, repeat sono-
graphic follow-up or repeat FNA may allow the patient
and physician to arguably detect any future malignancy
while still at a treatable stage. Further prospective study
of this hypothesis is required. Finally, one may argue
that our study should have been restricted to nodules
with indeterminate cytology as this population is in
whom mutational testing is currently recommended.
However, that was not the goal of our study as we
sought to investigate RAS-status in all nodules regardless
of cytology results. We believe this approach provided
Medici et al. BMC Medicine  (2015) 13:184 Page 8 of 9us the unique opportunity to investigate the natural
history and malignant risk of clinically relevant RAS-
positive nodules in an unbiased fashion.
Conclusions
In summary, our data depict the blinded, prospective
evaluation of RAS-mutational status in a population of
patients presenting with clinically relevant thyroid nod-
ules, and demonstrate a more indolent and variable
phenotype than previously described. RAS-positive thy-
roid nodules, especially in older individuals, frequently
demonstrate a benign phenotype. These data therefore
support the utility of FNA cytology in guiding the clin-
ical management of RAS-positive nodules. Cytologically
benign nodules, even if RAS-positive, may be candidates
for a non-operative observational strategy of repeated
sonographic evaluation or FNA. Even if malignant, most
RAS-positive thyroid nodules appear to be low-risk his-
tologically, and thus are likely to be highly treatable.
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